Proteo, Inc. is a clinical stage drug development company. It intends to develop, promote, and market pharmaceuticals and other biotech products. It focuses on the development of anti-inflammatory treatments for rare diseases with significant unmet needs. The company was founded by Oliver Wiedow and Birge Bargmann on December 18, 1992 and is headquartered in Irvine, CA.
Company profile
Ticker
PTEO, PTEO
Exchange
Website
CEO
Oliver Wiedow
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
American Flintlock Co, Page Active Holdings Inc, Trivantage Group Inc
SEC CIK
Corporate docs
Subsidiaries
Proteo Biotech AG ...
PTEO stock data
Latest filings (excl ownership)
SC 13E3/A
Going private transaction (amended)
22 Jul 20
15-12G
Securities registration termination
22 Jul 20
8-K
Material Modifications to Rights of Security Holders
20 Jul 20
8-K
Submission of Matters to a Vote of Security Holders
10 Jul 20
10-Q
2020 Q1
Quarterly report
5 Jun 20
DEFA14A
Additional proxy soliciting materials
26 May 20
SC 13E3/A
Going private transaction (amended)
26 May 20
DEFR14A
Revised proxy
26 May 20
CORRESP
Correspondence with SEC
26 May 20
UPLOAD
Letter from SEC
20 May 20
Latest ownership filings
SC 13G
Siebuhr Diethelm Achim DA
11 Mar 20
SC 13G
Bartels Kai Dieter
11 Mar 20
3
Diethelm Achim DA Siebuhr
11 Mar 20
3
Kai Dieter Bartels
11 Mar 20
4
REDEN JORK VON
14 Dec 18
3
REDEN JORK VON
26 Nov 18
4
Juergen Michael Paal
18 Apr 16
4
Juergen Michael Paal
28 Apr 15
4
Juergen Michael Paal
15 Apr 15
4
Juergen Michael Paal
13 Apr 15
Financial summary
| Quarter (USD) | Mar 20 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 284.90 k | 284.90 k | 284.90 k | 284.90 k | 284.90 k | 284.90 k |
| Cash burn (monthly) | (no burn) | (no burn) | 19.93 k | 18.63 k | 9.62 k | 16.56 k |
| Cash used (since last report) | n/a | n/a | 1.10 mm | 1.03 mm | 532.79 k | 917.60 k |
| Cash remaining | n/a | n/a | -819.24 k | -747.66 k | -247.89 k | -632.70 k |
| Runway (months of cash) | n/a | n/a | -41.1 | -40.1 | -25.8 | -38.2 |